Skip to main content
Premium Trial:

Request an Annual Quote

Telesis Bio, Cellibre Partner to Validate CRISPR Guide RNA Synthesis Instrument

NEW YORK — Telesis Bio — formerly Codex DNA — has kicked off a collaboration with manufacturing technology firm Cellibre to develop and validate an instrument for on-demand CRISPR-Cas9 guide RNA (gRNA) synthesis, the San Diego-based companies said on Wednesday.

Telesis is working to integrate its proprietary short oligonucleotide ligation assembly enzymatic DNA synthesis technology, which uses a library of short oligonucleotides that serve as building blocks to construct longer oligos, into its recently released BioXp 9600 benchtop synthetic biology system to create the BioXp Digital-to-Biological Converter instrument.

Under the partnership, Cellibre will use its in-house technologies and cell lines to evaluate and validate the system for automated gRNA synthesis, as well as to improve its own cell engineering workflows.

Additional terms of the alliance were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.